Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 562 | 118 | 434 |
| Samples | 177 | 50 | 125 |
| Peptides | 129 | 32 | 101 |
Function
RAD51D · RAD51 paralog D
The protein encoded by this gene is a member of the RAD51 protein family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51, which are known to be involved in the homologous recombination and repair of DNA. This protein forms a complex with several other members of the RAD51 family, including RAD51L1, RAD51L2, and XRCC2. The protein complex formed with this protein has been shown to catalyze homologous pairing between single- and double-stranded DNA, and is thought to play a role in the early stage of recombinational repair of DNA. Alternative splicing results in multiple transcript variants. Read-through transcription also exists between this gene and the downstream ring finger and FYVE-like domain containing 1 (RFFL) gene. [provided by RefSeq, Jan 2011].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 110 amino-acid changes on canonical ENST00000345365 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RAD51D · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RAD51D – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Acute Myeloid Leukemia | 4/90 4% | 0/0 0% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Burkitts Lymphoma | 3/32 9% | 1/196 1% |
| Germ Cell Tumour | 3/25 12% | 0/169 0% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Endometrial Carcinoma | 1/42 2% | 8/612 1% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 7/1390 0% |
| Colorectal Carcinoma | 7/143 5% | 18/3239 1% |
| Melanoma | 3/210 1% | 10/1899 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Gastric Carcinoma | 1/74 1% | 8/1809 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Other Solid Cancers | 0/94 0% | 7/1515 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 2/810 0% |
| Hepatocellular Carcinoma | 1/46 2% | 6/2210 0% |
| Glioma | 0/52 0% | 6/2127 0% |
| Other Sarcomas | 1/69 1% | 1/699 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 4/1592 0% |
| Pancreatic Carcinoma | 2/89 2% | 2/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 4/1574 0% |
| B-Cell Non-Hodgkins Lymphoma | 5/88 6% | 1/2534 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
Mutation Distribution
Where RAD51D is mutated · all tissues, split by cell line vs tissue
How many mutations in RAD51D were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 562 mutations in RAD51D
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|